Clinical Evidence Human Trials: A randomized, placebo-controlled study in obese adults demonstrated that AOD-9604 significantly reduced abdominal and total body fat over several weeks of treatment, without serious side effects Animal Studies: Preclinical studies in mice and rats showed that AOD-9604: Stimulated lipolysis Inhibited lipogenesis (formation of new fat) Prevented weight gain despite high-fat diets This dual actionenhancing fat breakdown and inhibiting fat formationpositions AOD-9604 as a potent tool for combating obesity
The coefficient of determination, R 2 , provides an estimate of the proportion of variance in the response variable explained by the model
While GHK-Cu is generally well-tolerated in topical research, certain contraindications or precautions should be considered, especially for systemic research or in specific populations: Systemic Research: For systemic applications, GHK-Cu is generally not recommended for subjects who are pregnant, breastfeeding, have active cancer, or suffer from Wilsons disease (a condition involving copper accumulation)
( ) GHK-Cu
The authors identified future areas of investigation including male models, long-term treatment effects, and combination with other NAD+ precursors such as NMN
:max_bytes(150000):strip_icc()/benefits-of-glutathione-89457_final-01-502464fe91b2444285b0cccf8cb0a33c.png)
